The CYP2C9 gene has several polymorphisms, the most common being CYP2C9*2 and CYP2C9*3. These polymorphisms can lead to reduced enzyme activity, affecting drug metabolism. For instance, individuals with these variants may require lower doses of warfarin to achieve therapeutic effects, reducing the risk of bleeding complications.
